University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma : why clinical trials might have failed and how they could succeed

Simple item page
dc.contributor.authorMeemanage, Madusha
dc.contributor.authorSpender, Lindsay C
dc.contributor.authorCollinson, Diane
dc.contributor.authorIannetta, Joanna
dc.contributor.authorChallapalli, Pranavi
dc.contributor.authorTurbitt, Julie
dc.contributor.authorClark, Caroline
dc.contributor.authorBaxter, Mark
dc.contributor.authorMurray, Graeme
dc.contributor.authorWalsh, Shaun
dc.contributor.authorMiedzybrodzka, Zofia
dc.contributor.authorPetty, Russell D
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.contributor.institutionUniversity of Aberdeen.Institute of Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.University of Aberdeenen
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Centre for Health Data Scienceen
dc.contributor.institutionUniversity of Aberdeen.Grampian Data Safe Haven (DaSH)en
dc.date.accessioned2021-03-09T21:59:01Z
dc.date.available2021-03-09T21:59:01Z
dc.date.issued2021-03-01
dc.descriptionAcknowledgements We thank Alice Savage for technical laboratory assistance. Funding The work undertaken was funded by Ninewells Cancer Campaign (Dundee) and Scottish Government Chief Scientist Office (Grant reference TCS/19/18).en
dc.description.statusPeer revieweden
dc.format.extent17
dc.format.extent1684384
dc.identifier180893311
dc.identifier98fe541f-5f26-4da9-b664-ed952b6fce93
dc.identifier33169187
dc.identifier85095711255
dc.identifier000587966100002
dc.identifier.citationMeemanage, M, Spender, L C, Collinson, D, Iannetta, J, Challapalli, P, Turbitt, J, Clark, C, Baxter, M, Murray, G, Walsh, S, Miedzybrodzka, Z & Petty, R D 2021, 'Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma : why clinical trials might have failed and how they could succeed', Cancer Chemotherapy and Pharmacology, vol. 87, pp. 361–377. https://doi.org/10.1007/s00280-020-04187-wen
dc.identifier.doi10.1007/s00280-020-04187-w
dc.identifier.issn0344-5704
dc.identifier.otherORCID: 0000-0003-2055-4572
dc.identifier.otherORCID: /0000-0003-2890-8136/work/175113392
dc.identifier.urihttps://hdl.handle.net/2164/16002
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85095711255&partnerID=8YFLogxKen
dc.identifier.vol87en
dc.language.isoeng
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectChemotherapy combinationsen
dc.subjectDocetaxelen
dc.subjectEGFRen
dc.subjectESCCen
dc.subjectGastroesophageal canceren
dc.subjectGefitiniben
dc.subjectPlatinumen
dc.subjectGEFITINIBen
dc.subjectMULTICENTERen
dc.subjectPROGNOSTIC VALUEen
dc.subjectCANCERen
dc.subjectPHASE-III TRIALen
dc.subjectGROWTH-FACTOR RECEPTORen
dc.subjectOVEREXPRESSIONen
dc.subjectAMPLIFICATIONen
dc.subjectTYROSINE KINASE INHIBITORen
dc.subjectGENE COPY NUMBERen
dc.subjectR Medicineen
dc.subjectPharmacology (medical)en
dc.subjectOncologyen
dc.subjectCancer Researchen
dc.subjectToxicologyen
dc.subjectPharmacologyen
dc.subjectOtheren
dc.subject.lccRen
dc.titleInteractions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma : why clinical trials might have failed and how they could succeeden
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Meemanage2021_etal_Interactions_between_VOR.pdf
Size:
1.61 MB
Format:
Adobe Portable Document Format
Download

Collections

All research